A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia

Does partial blockade of dopamine D2 receptors with Amisulpride cause anhedonia? An experimental study in healthy volunteers

(2023) Max Berg et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Effects of dopamine modulation on chronic stress-induced deficits in reward learning

(2022) Steven J. Lamontagne et al.   COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE

A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor

(2022) Lukasz Biernat et al.   PSYCHOPHARMACOLOGY

Discovery of Non‐racemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders

(2021) Seth C. Hopkins et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis

(2021) Caroline Zangani et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression

(2021) Antony Loebel et al.   JOURNAL OF AFFECTIVE DISORDERS

Bipolar disorders

(2020) Roger S McIntyre et al.   LANCET

AMISULPRIDE AS AN AUGMENTATION AGENT IN TREATMENT RESISTANT DEPRESSION: A CASE SERIES AND REVIEW OF THE LITERATURE

(2019) Hans Rittmannsberger et al.   Psychiatria Danubina

Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7

(2019) Vincent Grattan et al.   ACS Omega

Current Concepts and Treatments of Schizophrenia

(2018) Piotr Stępnicki et al.   MOLECULES

The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family

(2014) Joao N. Dos Santos Pereira et al.   AAPS Journal

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial

(2014) Suresh Durgam et al.   BIPOLAR DISORDERS

Amisulpride promotes cognitive flexibility in rats: The role of 5-HT7 receptors

(2013) Agnieszka Nikiforuk et al.   BEHAVIOURAL BRAIN RESEARCH

Dopamine D3 receptor as a new pharmacological target for the treatment of depression

(2013) Gian Marco Leggio et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression

(2012) Mauricio Tohen et al.   BRITISH JOURNAL OF PSYCHIATRY

Getting specialized: presynaptic and postsynaptic dopamine D2 receptors

(2009) Claudia De Mei et al.   CURRENT OPINION IN PHARMACOLOGY

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

(2009) Atheir I. Abbas et al.   PSYCHOPHARMACOLOGY

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

(2008) René S Kahn et al.   LANCET

Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study

(2008) E. Meisenzahl et al.   PHARMACOPSYCHIATRY